GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

Digital health care platform GoodRx has announced three senior-level leadership appointments, naming Raj Beri as chief operating offer, Mark Hull as chief product officer and Vina Leite as chief people officer, according to a Monday (May 9) press release. The publicly traded company said in its release that the executives were added “to support the […]

GoodRx Bolsters Top Ranks With Hires From Uber and Meta

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, has released its first quarter 2022 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com. GoodRx management will host a conference call and webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. First Quarter

GoodRx Releases First Quarter 2022 Financial Results

AMN Healthcare Services

AMN vs. GDRX: Which Stock Is the Better Value Option?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it has made key leadership appointments to support the company's scaling business and accelerate innovation to bring more affordable and convenient healthcare to consumers across the country. Raj Beri will join GoodRx as the company's first ever Chief Operating Officer (COO) from Uber, where he served as Vice President of Grocery and New Verticals, overseeing the

GoodRx Appoints Raj Beri as Chief Operating Officer, Mark Hull as Chief Product Officer and Vina Leite as Chief People Officer

GoodRx Holdings, Inc. (GDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GoodRx Holdings, Inc. (GDRX) Earnings Expected to Grow: Should You Buy?

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings, Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced that executives from the Company will be presenting at the RBC Capital Markets 2022 Global Healthcare Conference in New York, NY on Tuesday, May 17, at 1:35 p.m. Eastern Time (10:35 a.m. Pacific Time). A live webcast of the presentation will be available on the Company's Investor Relations website, https://investors.goodrx.com/. Following the confe

GoodRx to Present at the RBC Capital Markets 2022 Global Healthcare Conference

AppLovin Corp

Embraer

Insulet

Vonage Hlds

Get rid of toxic stocks like GoodRx (GDRX), Insulet (PODD), Vonage (VG), AppLovin (APP) and Embraer (ERJ) to avoid portfolio bleeding.

Refresh Your Portfolio by Dumping These 5 Toxic Stocks

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced a new effort with AssistRx to bring broader awareness and access to branded and specialty medication therapy initiation. GoodRx will leverage its large provider reach to drive attention to AssistRx's iAssist platform, which gives providers immediate access to a patient's coverage, improved price transparency and the right prior authorization information. Specialt

GoodRx Teams Up with AssistRx to Increase Provider Awareness of Simplified Specialty Medication and Treatment Initiation

Shares of GoodRx have been in crisis this year, falling more than 50% year to date. The stock crumbled especially after releasing Q4 results in late February, which showcases poorer growth and guidance than expected.

GoodRx: Time To Buy The Dip

TherapeuticsMD

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (NASDAQ: TXMD), (“TXMD” or the “Company”) an innovative, leading women's healthcare company, announced today the closing of the divestiture of vitaCare Prescription Services to GoodRx (NASDAQ: GDRX), in a cash transaction valued at $150 million, subject to a working capital adjustment. The Company previously announced the signing of a definitive agreement on March 6, 2022. TherapeuticsMD remains eligible to receive an additional $7 million

TherapeuticsMD Completes the Divestiture of vitaCare Prescription Services to GoodRx in a Cash Transaction Valued at $150 Million

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced the completion of its previously announced acquisition of vitaCare for $150 million in cash, with an additional $7 million of consideration contingent payment upon vitaCare's financial performance through 2023. VitaCare is a pharmacy services platform that expands GoodRx's offering to pharmaceutical manufacturers while helping to improve patient access and adhere

GoodRx Closes Acquisition of vitaCare, A Tech-Enabled Pharmacy Services Platform

Astronics

Atlantica Sustainable Infrastructure

Las Vegas Sands

Safeguard your portfolio by dumping these toxic stocks- Atlantica Yield (AY), Astronics (ATRO), GoodRx (GDRX) and Las Vegas Sands (LVS).

Beware of These 4 Toxic Stocks Amid Market Uncertainty

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx Holdings Inc. (Nasdaq: GDRX), a leading consumer-focused digital healthcare platform, today announced it will release its first quarter 2022 financial results after U.S. markets close on Monday, May 9, 2022. GoodRx management will hold a conference call and webcast that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss the results and the Company's business outlook. Prior to the call, GoodRx will issue a press release containing a li

GoodRx Announces Date for First Quarter 2022 Earnings Release and Conference Call

This Pummeled Healthcare Stock Could Come Roaring Back

Airbnb

Booking Hlds

Netflix

Spotify

This quarter's results will be the first to reflect the impact of Russia's invasion of Ukraine, as well as a sharp jump in both interest rates and fuel prices.

Netflix and Other Internet Companies Report Earnings Soon. Don't Get Your Hopes Up.

Starbucks

The Worst Is Still to Come for These 2 Crashing Stocks

Investors were not happy with the company's latest earnings results, nor with its 2022 guidance.

Why GoodRx Tanked by 29.5% in March

AMN or GDRX: Which Is the Better Value Stock Right Now?

AMN vs. GDRX: Which Stock Should Value Investors Buy Now?

Pharmaceutical drug savings and digital healthcare platform GoodRx (NASDAQ: GDRX) stock has falling to all-time lows accelerated by the sell-off in benchmark indexes

GoodRx Stock is a Potential Buy the Dip Opportunity

Baird analysts say the stock's valuation is more attractive after a significant selloff.

GoodRx Pullback Is 'Attractive Entry Point.' Why This Analyst Upgraded the Stock.

Trouble might be brewing on a few fronts.

3 Things About GoodRx That Smart Investors Know

The stock was trading at just under $28 before its earnings numbers were posted. Now it's down to less than $16.

Should You Buy GoodRx After Its Massive 40% Post-Earnings Crash?

GoodRx Holdings Inc (NASDAQ: GDRX) recently announced it is buying vitaCare for $150 million. These are the details.

Why GoodRx (GDRX) Is Buying vitaCare For $150 Million

Digital healthcare platform GoodRx is set to acquire vitaCare Prescription Services from TherapeuticsMD for $150 million, the company announced Monday (March 7). The vitaCare platform helps patients understand their health coverage, identify ways to save and facilitates communication between payors and providers, while also providing a path to get prescriptions filled through its network of […]

News for GoodRx Holdings Stock (GDRX)